PCVX vs. TEVA: Vaxcyte vs. Teva Pharmaceutical Stock Comparison

Company Profile

Vaxcyte (PCVX) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Teva Pharmaceutical (TEVA) has more than two decades of public-market history since February 16, 1982, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Vaxcyte (PCVX) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.

Both Vaxcyte (PCVX) at 0.00% and Teva Pharmaceutical (TEVA) at 2.94% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Teva Pharmaceutical (TEVA) reports revenue growth of 4.31%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Neither Vaxcyte (PCVX) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Vaxcyte (PCVX) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Vaxcyte (PCVX) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Vaxcyte (PCVX) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

A sales-based read is only available for Teva Pharmaceutical (TEVA), whose P/S ratio of 2.89 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

On P/B ratio, both Vaxcyte (PCVX) at 3.83 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics